Charting the course of electroconvulsive therapy

Where have we been and where are we headed?

Research output: Contribution to journalArticle

Abstract

Electroconvulsive therapy (ECT) is one of the oldest and best treatments for severe mental illness. A safe and highly effective option for treatment-resistant mood disorders, ECT can be a lifesaving treatment for people suffering from catatonia and acute suicidality. Less recognized are the benefits of ECT in the treatment of primary psychotic disorders, Parkinson’s disease, and status epilepticus. Evidence from multisite clinical trials in the past decade shows an evolving standard for the delivery of ECT to achieve and maintain remission and quality of life. Today, the optimal practice of ECT is defined by evidence-based treatment planning, including patient selection, choice of electrode placement and stimulus parameters, augmentation with pharmacotherapy, and the use of continuation/maintenance treatment. Research into biomarkers and neuroplasticity related to ECT response, as well as new investigational methods of delivering ECT, provide a glimpse into the future of this time-tested treatment.

Original languageEnglish (US)
Pages (from-to)647-651
Number of pages5
JournalPsychiatric Annals
Volume46
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Electroconvulsive Therapy
Therapeutics
Catatonia
Neuronal Plasticity
Status Epilepticus
Mood Disorders
Psychotic Disorders
Patient Selection
Parkinson Disease
Electrodes
Biomarkers
Quality of Life
Clinical Trials
Drug Therapy
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

@article{68d651d788784c6cb503b0ef32343ed9,
title = "Charting the course of electroconvulsive therapy: Where have we been and where are we headed?",
abstract = "Electroconvulsive therapy (ECT) is one of the oldest and best treatments for severe mental illness. A safe and highly effective option for treatment-resistant mood disorders, ECT can be a lifesaving treatment for people suffering from catatonia and acute suicidality. Less recognized are the benefits of ECT in the treatment of primary psychotic disorders, Parkinson’s disease, and status epilepticus. Evidence from multisite clinical trials in the past decade shows an evolving standard for the delivery of ECT to achieve and maintain remission and quality of life. Today, the optimal practice of ECT is defined by evidence-based treatment planning, including patient selection, choice of electrode placement and stimulus parameters, augmentation with pharmacotherapy, and the use of continuation/maintenance treatment. Research into biomarkers and neuroplasticity related to ECT response, as well as new investigational methods of delivering ECT, provide a glimpse into the future of this time-tested treatment.",
author = "Rosenquist, {Peter B.} and McCall, {William Vaughn} and Youssef, {Nagy Adel}",
year = "2016",
month = "11",
day = "1",
doi = "10.3928/00485713-20160927-01",
language = "English (US)",
volume = "46",
pages = "647--651",
journal = "Psychiatric Annals",
issn = "0048-5713",
publisher = "Slack Incorporated",
number = "11",

}

TY - JOUR

T1 - Charting the course of electroconvulsive therapy

T2 - Where have we been and where are we headed?

AU - Rosenquist, Peter B.

AU - McCall, William Vaughn

AU - Youssef, Nagy Adel

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Electroconvulsive therapy (ECT) is one of the oldest and best treatments for severe mental illness. A safe and highly effective option for treatment-resistant mood disorders, ECT can be a lifesaving treatment for people suffering from catatonia and acute suicidality. Less recognized are the benefits of ECT in the treatment of primary psychotic disorders, Parkinson’s disease, and status epilepticus. Evidence from multisite clinical trials in the past decade shows an evolving standard for the delivery of ECT to achieve and maintain remission and quality of life. Today, the optimal practice of ECT is defined by evidence-based treatment planning, including patient selection, choice of electrode placement and stimulus parameters, augmentation with pharmacotherapy, and the use of continuation/maintenance treatment. Research into biomarkers and neuroplasticity related to ECT response, as well as new investigational methods of delivering ECT, provide a glimpse into the future of this time-tested treatment.

AB - Electroconvulsive therapy (ECT) is one of the oldest and best treatments for severe mental illness. A safe and highly effective option for treatment-resistant mood disorders, ECT can be a lifesaving treatment for people suffering from catatonia and acute suicidality. Less recognized are the benefits of ECT in the treatment of primary psychotic disorders, Parkinson’s disease, and status epilepticus. Evidence from multisite clinical trials in the past decade shows an evolving standard for the delivery of ECT to achieve and maintain remission and quality of life. Today, the optimal practice of ECT is defined by evidence-based treatment planning, including patient selection, choice of electrode placement and stimulus parameters, augmentation with pharmacotherapy, and the use of continuation/maintenance treatment. Research into biomarkers and neuroplasticity related to ECT response, as well as new investigational methods of delivering ECT, provide a glimpse into the future of this time-tested treatment.

UR - http://www.scopus.com/inward/record.url?scp=84994877372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994877372&partnerID=8YFLogxK

U2 - 10.3928/00485713-20160927-01

DO - 10.3928/00485713-20160927-01

M3 - Article

VL - 46

SP - 647

EP - 651

JO - Psychiatric Annals

JF - Psychiatric Annals

SN - 0048-5713

IS - 11

ER -